Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy.

International journal of cancer - 15 Feb 2012

Bao Bo-Ying, Pao Jiunn-Bey, Huang Chun-Nung, Pu Yeong-Shiau, Chang Ta-Yuan, Lan Yu-Hsuan, Lu Te-Ling, Lee Hong-Zin, Chen Lu-Min, Ting Wen-Chien, Hsieh Chi-Jeng, Huang Shu-Pin

Abstract excerpt

Androgen-deprivation therapy (ADT) is the most common therapy for advanced prostate cancer, but the prognosis significantly differs among individuals. In this study, we evaluated recently identified 19 prostate cancer susceptibility variants as prognostic predictors for the survival after ADT. A total of 601 prostate cancer patients treated with ADT were enrolled in this study cohort. The prognostic significance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Androgen Antagonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Polymorphism, Single Nucleotide

Share to Prognosis

Share to Proportional Hazards Models

Share to Prostatic Neoplasms

Source

Identifiers

PMID: 21445969
DOI: 10.1002/ijc.26091

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy.PMID 21445969Read ↗

Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy.Semantic proximity Read ↗

Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy.Semantic proximity Read ↗

Association of rs6983561 polymorphism at 8q24 with prostate cancer mortality in a Japanese population.Semantic proximity Read ↗

Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer.Semantic proximity Read ↗

Association of Missense Polymorphism inHSD3B1With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or AbirateroneSemantic proximity Read ↗

Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality.Semantic proximity Read ↗

Correlation between Genomic Variants and Worldwide Epidemiology of Prostate Cancer.Semantic proximity Read ↗

Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies.Semantic proximity Read ↗

Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.Semantic proximity Read ↗

Genome-wide association study of prostate cancer-specific survival.Semantic proximity Read ↗

Genetic variants in nuclear factor-kappa B binding sites are associated with clinical outcomes in prostate cancer patients.Semantic proximity Read ↗

Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.